- Parties: The plaintiffs were Bayer Inc and Regeneron Pharmaceuticals, Inc. The defendant was Amgen Canada Inc.

- Subject Matter: This action involved the Patented Medicines (NOC) Regulations.

- Date: The action was discontinued by the plaintiffs, with the consent of the defendant, as of August 18, 2025. This discontinuance was filed in the Toronto office and marks the conclusion of the case unless further proceedings are initiated.

- Venue: This was a federal case before the Federal Court.

- Amount: No financial award was specified.